Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

MEDIA ALERT & PRESS TELECONFERENCE: 28th EORTC-NCI-AACR SYMPOSIUM5444811/21/2016 6:06:59 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx84False2016-11-21T18:00:00Z“Molecular Targets and Cancer Therapeutics”<div class="ExternalClassAFD4DC50453F4FB2B2A2D4D6FDB34F20"><p>MEDIA ALERT &amp; PRESS TELECONFERENCE</p><p>28th EORTC-NCI-AACR SYMPOSIUM<br>“Molecular Targets and Cancer Therapeutics”</p><p>Tuesday 29 November to Friday 2 December 2016, Munich, Germany.</p><p>A press conference will take place at 17.00 hrs CET (16.00 hrs GMT, 11.00 hrs ET) on Tuesday 29 November, Room Königssee, 2nd floor, ICM Messe München, Munich, Germany. This will include&#58;<br>•&#160;A joint statement by Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC), and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), on the need for improved partnerships and funding for cancer research (embargoed to 18.00 hrs CET on Tuesday 29 November).<br>•&#160;A preview by Professor Jean-Charles Soria (chair of the Symposium executive scientific committee, EORTC) of groundbreaking research being presented on Thursday 1 December, focusing on three studies on targeted therapies and liquid biopsy (embargoed to 00.01 hrs CET on Thursday 1 December).<br>•&#160;Suggestions and navigational tips from Professor Soria, Professor Lee Helman (scientific co-chair, NCI) and Dr. George Demetri (member of the AACR Board of Directors) on sessions and presentations during the Symposium that the scientific committee think may be of interest to journalists.</p><p>If you want to join the press conference by telephone please email Gwydion Lyn&#58; <a href="mailto&#58;Gwydion.Lyn@ecco-org.eu">Gwydion.Lyn@ecco-org.eu</a> (copying in Emma Mason/Kerry Noble&#58; <a href="mailto&#58;info@ricemason.eu">info@ricemason.eu</a>) to register your interest and receive dial-in details.</p><p>There will be a full media programme and there is still time for journalists to register online&#58; <a href="http&#58;//www.ecco-org.eu/Events/ENA2016/Media" target="_blank">http&#58;//www.ecco-org.eu/Events/ENA2016/Media</a></p><p>NB&#58; you will need to register to join the press conference even if you are unable to attend the Symposium in Munich. </p><p>The media programme will include&#58;<br>•&#160;The revolution in our understanding of the molecular basis is leading to dramatic responses to targeted therapies in advanced and metastatic cancer&#58; results from three groundbreaking studies show early benefit to patients.<br>•&#160;What effect does alternately flooding and starving prostate cancer cells with testosterone have?<br>•&#160;Results from a trial of the experimental drug TAS-114 in combination with a 5-FU-based chemotherapy in patients with advanced non-small cell lung cancer, pancreatic, breast and colorectal cancers.<br>•&#160;Difficult-to-treat advanced soft tissue sarcomas respond to a combination of new and existing anti-cancer drugs.<br>•&#160;Results from a trial of LY3039478, a Notch inhibitor, in patients with advanced cancer of the breast, colon, paratid (salivary gland) and sarcoma.<br>•&#160;Latest results from a trial of a new drug, CB-839, in combination with everolimus in kidney cancer patients.</p><p>The EORTC, AACR and the USA’s National Cancer Institute (NCI) are joining forces for the Symposium&#58; <a href="http&#58;//www.ecco-org.eu/Events/ENA2016" target="_blank">http&#58;//www.ecco-org.eu/Events/ENA2016</a> where the latest advances in pre-clinical and clinical research will be presented. Around 2,200 international experts will be discussing innovations in drug development, target selection and the impact of new discoveries in molecular biology.</p><p>For media queries about the Symposium, contact&#58;</p><p>EORTC media consultants&#58;<br>Emma Mason<br>Email&#58; <a href="mailto&#58;wordmason@mac.com">wordmason@mac.com</a> <br>Mobile&#58; +44 (0)7711 296 986</p><p>Kerry Noble<br>Email&#58; <a href="mailto&#58;kerry_noble@hotmail.com">kerry_noble@hotmail.com</a> <br>Mobile&#58; +44 (0)7446 869 433</p><p>&#160;</p></div>
2016 San Antonio Breast Cancer Symposium to Be Held Dec. 6-101199811/7/2016 5:16:47 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx82False2016-11-07T15:00:00Z<div class="ExternalClassB1A05C22042846729664EEDD9D4F4B20"><p class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6">​SAN ANTONIO — The Cancer Therapy &amp; Research Center at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research, and Baylor College of Medicine will be hosting the <a href="http&#58;//www.sabcs.org/" target="_blank">2016 San Antonio Breast Cancer Symposium</a>, Dec. 6-10, at the Henry B. Gonzalez Convention Center, San Antonio.</p><p class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6">The symposium provides news on state-of-the-art breast cancer research, including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.</p><p class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6">View the scientific program <a href="https&#58;//www.sabcs.org/Program/Schedule-at-a-Glance">here</a>. </p><p class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6">Press conferences will take place at 7&#58;30 a.m. CT on&#160;Wednesday, Dec. 7; Thursday, Dec. 8; and Friday, Dec. 9.</p><p class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6">The press room will be open during the following days/times&#58;</p><div class="ExternalClassC03F5A6598DD48AE9535202DCC9F49B6"><ul><li>Tuesday, Dec. 6&#58;<br>8 a.m. to 7 p.m. CT</li><li>Wednesday, Thursday, and Friday, Dec. 7, 8, and 9&#58;<br>7 a.m. to 7 p.m. CT</li></ul></div><p><em>Please note the press office will not be open on Saturday, Dec. 10.</em></p><p>A press kit containing releases and highlighted abstracts will be available in early December.</p><p>Registration will be available to members of the media who provide credentials. For more information or to register for the meeting please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155, Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org" target="_blank">julia.gunther@aacr.org</a> or 215-446-6896, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org" target="_blank">jeff.molter@aacr.org</a> or 215-446-7233.</p><p><a href="http&#58;//www.sabcs.org/Hotel" target="_blank">Reserve a hotel room</a>.&#160;</p></div>
Philadelphia-area Cycling Event to Raise Funds for Cancer Research1199910/20/2016 4:50:50 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx83False2016-10-20T16:30:00Z<div class="ExternalClass9E69BCD7CFEB44B9BF94845FCBF64083"><p>​WHAT&#58;&#160;Hundreds to participate in Spintensity 200, a cycling event to raise funds for advancing cancer research to cure and prevent the more than 200 types of cancer. Proceeds support cancer research at the American Association for Cancer Research (AACR), the world’s first and largest cancer research organization, which is headquartered in Philadelphia.</p><p><br>WHO&#58;&#160;Cancer survivors, those touched by cancer, and the community<br>Six Spintensity 200 instructors<br>Mitch Stoller, executive director, AACR Foundation<br>9 a.m. session&#58; ambassador and cancer survivor Jeanette Stephens-El<br>1 p.m. session&#58; ambassador and two-time cancer survivor Suzanne Kulliver</p><p><br>WHEN&#58;&#160;Saturday, Nov. 5<br>Two 200-minute cycling sections&#58;<br>9 a.m. to noon<br>1 p.m. to 4 p.m.<br></p><p>WHERE&#58;&#160;&#160;Simeone Foundation Automotive Museum<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6825 Norwitch Drive<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Philadelphia, PA&#160; 19153</p></div>
AACR and FDA Present Workshop on Immuno-Oncology Drug Development1199710/12/2016 2:04:46 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx81False2016-10-12T14:00:00Z<div class="ExternalClass539ECFD7E77741AA8E51828469DEE3D2"><p>​The U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) present a two-day workshop on <strong>immuno-oncology drug development</strong>, open to the public in person or via live stream on Thursday, October 13, and Friday, October 14.</p><p>The workshop program brings together individuals representing many of the stakeholders in the immune-oncology drug development community, and is designed to provide an interdisciplinary forum to foster robust scientific discussion on the need and potential for&#58;</p><ul><li><p>new nonclinical toxicology models;</p></li><li><p>modifications to traditional clinical safety monitoring;</p></li><li><p>new efficacy endpoints and statistical analysis methods, and modifications of traditional endpoints; and</p></li><li><p>novel trial designs in immuno-oncology clinical trials.</p></li></ul><p><strong>Workshop Co-chairs&#58; </strong></p><p><strong>Maitreyee Hazarika, MD</strong>, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA&#160;</p><p><strong>Marc Theoret, MD</strong>, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA&#160;</p><p><strong>Suzanne L. Topalian, MD</strong>, Member, AACR Regulatory Science and Policy Subcommittee; Professor, Surgery and Oncology, Johns Hopkins University School of Medicine; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Associate Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy&#160;</p><p><strong>Jedd D. Wolchok, MD, PhD</strong>, Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation Chief; Melanoma &amp; Immunotherapeutics Service Director; Director, Parker Institute for Cancer Immunotherapy at MSK; Associate Director, Ludwig Center for Cancer Immunotherapy; Member, Ludwig Cancer Research; Professor of Medicine, Weill Medical College of Cornell University; Memorial Sloan Kettering Cancer Center</p><p>This FDA-AACR workshop is part of a series dedicated to supporting the efforts of the FDA to modernize the regulatory process and accommodate the fast pace of innovation in science and technology.</p><p>WHEN&#58; Thursday, Oct. 13 and Friday, Oct. 14;&#160;8 a.m. to 5 p.m.</p><p>WHERE&#58; Hyatt Regency Washington on Capitol Hill, 400 New Jersey Avenue, NW,&#160;Washington, D.C.&#160; 20001</p><p>To register for this AACR-FDA Workshop or obtain program information, please contact Rachel Salis-Silverman at <a href="mailto&#58;Rachel.silverman@aacr.org" target="_blank">Rachel.silverman@aacr.org</a> or 215-446-7159 or Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155.</p></div>
Cancer Today Fall Issue Addresses LGBT Cancer Care1199610/6/2016 4:24:19 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx80False2016-10-06T15:00:00Z<div class="ExternalClass40920D47502949039B33B76D0415A39C"><p>​PHILADELPHIA — The Fall 2016 issue of <a href="http&#58;//www.cancertodaymag.org/"><em>Cancer Today</em></a>, a publication of the <a href="/Pages/Home.aspx">American Association for Cancer Research </a>(AACR), features “<a href="http&#58;//www.cancertodaymag.org/Fall2016/Pages/Cancer-Comes-Out-LGBT.aspx" target="_blank">Cancer Comes Out</a>.” The lesbian, gay, bisexual, and transgender (LGBT) community faces unique challenges in being diagnosed and treated for cancer. Efforts are underway to better serve this diverse population. </p><p>Published quarterly by the AACR, <em>Cancer Today </em>is an authoritative resource for cancer patients, survivors, and their family members and friends. In every issue, <em>Cancer Today </em>offers information and inspiration to help readers face the challenges of diagnosis, treatment, survivorship, and caregiving.</p><p>This issue of <em>Cancer Today </em>also includes “<a href="http&#58;//www.cancertodaymag.org/Fall2016/Pages/Reasons-to-Dream-Lung-Cancer-Emily-Bennett-Taylor-Fertility.aspx" target="_blank">Reasons to Dream</a>,” a profile of Emily Bennett Taylor, a stage IV lung cancer survivor and mother of twins. “<a href="http&#58;//www.cancertodaymag.org/Fall2016/Pages/A-Rural-Challenge-Disparities-technology.aspx" target="_blank">A Rural Challenge</a>” describes how health care providers are extending cancer care to remote areas through on-site visits and advanced technology. “<a href="http&#58;//www.cancertodaymag.org/Fall2016/Pages/A-Force-of-Nature-Eartha-Kitt-Colorectal-Cancer.aspx" target="_blank">A Force of Nature</a>” tells the story of singer, dancer, and actress Eartha Kitt and her experience with colorectal cancer.</p><p>To read these stories and others, go to <a href="http&#58;//www.cancertodaymag.org/"><em>Cancer Today</em></a>, or follow the magazine on Facebook at <a href="https&#58;//www.facebook.com/CancerToday" target="_blank">facebook.com/CancerToday </a>and Twitter at <a href="https&#58;//twitter.com/CancerTodayMag" target="_blank">twitter.com/CancerTodayMag</a>. </p><p>Media are welcome to use information from <em>Cancer Today</em>; however, we ask that you cite the source.</p></div>
Leading Cancer Research Organizations to Host Cancer Immunotherapy Conference119949/14/2016 3:14:48 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx79False2016-09-14T14:00:00ZPress Luncheon Slated for 12:15 p.m. ET, Monday, Sept. 26<div class="ExternalClass8AFBF6BA1F1C4099B1E2CEF3B9734586"><p>NEW YORK – The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second <a href="http&#58;//www.cancerimmunotherapyconference.org/" target="_blank">International Cancer Immunotherapy Conference</a> at the Sheraton New York Times Square Hotel (811 7th Ave., New York) and the New York Hilton Midtown (1335 Avenue of the Americas, New York), Sept. 25-28, 2016.</p><p>A press luncheon providing insights about the meeting from immunotherapy leaders and presenting investigators will be held from 12&#58;15 – 1&#58;15 p.m. ET, on Monday, Sept. 26, in the Riverside Suite (third floor) at the Sheraton New York Times Square Hotel. </p><p>Press luncheon&#58;</p><p><strong>Moderator&#58; </strong>Philip Greenberg, MD, conference co-chair; member, Clinical Research Division and head, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle; co-editor-in-chief, <em>Cancer Immunology Research</em></p><p><strong>Presenters&#58;<br></strong><strong>AACR&#58;</strong> Elizabeth Jaffee, MD, deputy director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore; member, AACR Board of Directors (2013-2016)</p><p><em>Current developments and challenges in immunotherapy</em></p><p><strong>CRI&#58;</strong> Jill O'Donnell-Tormey, CEO and director of scientific affairs, CRI<br><em>Current developments and challenges in immunotherapy</em></p><p>Aung Naing, MD, associate professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston<br><em>Brief overview of study presented at conference</em></p><p>Alexander Huang, MD, clinical fellow, Division of Hematology/Oncology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia<br><em>Brief overview of study presented at conference</em></p><p><strong>Question and answer session with the media</strong></p><p><strong>Additional representatives&#58;</strong> Christine Castle, managing director, CIMT; and Lorenzo Galluzzi, PhD, associate director, EATI, will be present to serve as additional resources to media. </p><p>The meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including&#58;&#160; immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. </p><p>The full meeting program is available <a href="http&#58;//www.cancerimmunotherapyconference.org/program-of-events/" target="_blank">here</a>.</p><p>There will be a press room located in Room Liberty 3 (third floor) at the Sheraton New York Times Square. Press room hours will be&#58; Sept. 25-27, 8 a.m. to 5 p.m. ET; and Sept. 28, 8 a.m. to noon ET.</p><p>Registration is complimentary for credentialed news media. Members of the media can register using this form. Return completed forms to Lauren Riley via email at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or via fax at 215-446-7291.</p><p>Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley.</p><p>Those following on social media can join the conversation on Twitter at #cicon16.</p><p>For more information, contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org%20or">lauren.riley@aacr.org or</a> 215-446-7155 or Elliot Fox at <a href="mailto&#58;efox@w2ogroup.com">efox@w2ogroup.com</a> or 212-257-6724.<br></p></div>
AACR Cancer Health Disparities Conference Set for Sept. 25-28 in Fort Lauderdale, Florida119939/12/2016 2:15:44 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx77False2016-09-12T14:00:00Z<div class="ExternalClass6BA88186F09343EA92F012119D3F7C98"><p>​FORT LAUDERDALE, FLORIDA — The <a href="http&#58;//media.ne.cision.com/l/fclsjhzs/www.aacr.org/">American Association for Cancer Research</a> (AACR) will host its ninth annual conference, <a href="http&#58;//media.ne.cision.com/l/fclsjhzs/www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=90">The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved</a>, Sept. 25-28, at the Westin Fort Lauderdale Beach Resort.</p><p>The conference, held in association with the <a href="/Membership/Pages/Constituency%20Groups/minorities-in-cancer-research___1C81B8.aspx#.V4-DtRJRIXE">AACR Minorities in Cancer Research Council</a>, aims to advance the understanding and, ultimately, help to eliminate the disparities in cancer that represent a major public health problem in our country.&#160;</p><p>The full meeting program is available <a href="http&#58;//media.ne.cision.com/l/fclsjhzs/www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=90&amp;ItemID=221&amp;DetailItemID=">here</a>.</p><p>A press program highlighting several newsworthy studies being presented at the meeting will be distributed to reporters under embargo prior to the meeting.</p><p>Registration will be available for credentialed news media. For more information, or to register for the meeting, please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965.</p><p>Follow the meeting on Twitter&#58; <a href="https&#58;//wpyadmin.ne.cision.com/l/fclsjhzs/twitter.com/search?f=realtime&amp;q=%23SAACRdisp16">#AACRdisp16</a></p></div>
Leading Cancer Research Organizations to Host Cancer Immunotherapy Conference119928/15/2016 6:26:18 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx76False2016-08-15T17:05:00ZPress Luncheon Slated for 12:15 p.m. ET, Monday, Sept. 26<div class="ExternalClass781D149DAA66483587A9E2B3EA7FC0E6"><p>​NEW YORK – The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second <a target="_blank" href="http&#58;//www.cancerimmunotherapyconference.org/">International Cancer Immunotherapy Conference</a> at the Sheraton New York Times Square Hotel (811 7th Ave., New York) and the New York Hilton Midtown (1335 Avenue of the Americas, New York), Sept. 25-28, 2016.</p><p>A press luncheon providing insights about the meeting from immunotherapy leaders and presenting investigators will be held from 12&#58;15 – 1&#58;15 p.m. ET, on Monday, Sept. 26, at the Sheraton New York Times Square Hotel. </p><p>The meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including&#58; &#160;immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. </p><p>The full program is available <a target="_blank" href="http&#58;//www.cancerimmunotherapyconference.org/program-of-events/">here</a>.</p><p>Registration is complimentary for credentialed news media. Members of the media can register using <a target="_blank" href="http&#58;//www.cancerimmunotherapyconference.org/s/ICI-2016-REG-FORM.pdf">this form</a>. Return completed forms to Lauren Riley via email at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or via fax at 215-446-7291.</p><p>Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley.</p><p>Those following on social media can join the conversation on Twitter at <a href="https&#58;//twitter.com/hashtag/CICON16?src=hash">#cicon16</a>.</p><p>For more information, contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155 or Elliot Fox at <a href="mailto&#58;efox@w2ogroup.com">efox@w2ogroup.com</a> or 212-257-6724.</p></div>
EXPERT ADVISORY: AACR Leaders in Cancer Research and Patient Care at Today’s White House-hosted Cancer Moonshot Summit Available for Media Interviews119916/30/2016 1:38:51 AMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx74False2016-06-29T17:00:00Z<div class="ExternalClass3C18C4A309AA4FB1A4284272C196190F"><p>​PHILADELPHIA — Today,&#160;American Association for Cancer Research&#160;President Nancy Davidson, MD, and AACR chief executive officer Margaret Foti, PhD, MD (hc), are participating in the Cancer Moonshot Summit hosted by the White House. Davidson, who is the director of the University of Pittsburgh Cancer Institute, is a physician-scientist who specializes in breast cancer, and can speak to the opportunities associated with propelling the field forward both in her personal work and as a leader in the cancer research community.</p><p>As the leader of the largest cancer research organization in the world, Foti has served as a catalyst, convening the greatest minds in cancer research and fostering collaboration among all stakeholders, including those in academia, government, industry, and the patient community.</p><p>Davidson and Foti's participation in today's summit dovetails on the AACR congressional briefing held yesterday about the National Cancer Moonshot Initiative. The briefing featured National Cancer Institute's acting director Douglas Lowy, MD, and five early-career investigators who provided their fresh perspectives on areas of needed focus to achieve the Cancer Moonshot's goal of accomplishing a decade's worth of progress in five years. The Briefing was broadcasted LIVE on Facebook, and can be viewed here&#58; <a href="https&#58;//www.facebook.com/aacr.org/videos/10154354430633631/" target="_blank">https&#58;//www.facebook.com/aacr.org/videos/10154354430633631/</a></p><p>Hosting yesterday's briefing builds upon the AACR's thought leadership in this national effort to cure cancer. In April, Vice President Joe Biden spoke to 4,500 in the cancer research community at the AACR Annual Meeting 2016. On June 1, the Blue Ribbon Panel hosted a special session with AACR leaders and early-stage investigators and minority researchers.</p><p>Prior to the announcement in January of the vice president's cancer initiative, 15 distinguished AACR leaders and members representing 10 medical institutions and nine states met with Biden's staff to discuss areas of considerable promise in cancer research, including precision medicine, immunotherapy, and potential collaboration around big data, citing <a href="/RESEARCH/RESEARCH/PAGES/AACR-PROJECT-GENIE.ASPX" target="_blank">AACR Project GENIE</a> as an example. Shortly thereafter, Biden invited the AACR's president and two past presidents to provide their thoughts and guidance at a special session, &quot;Cancer Moonshot&#58; A Call to Action,&quot; at the World Economic Forum in Davos, Switzerland.</p><p>Since then, Biden has continued to meet with AACR members as he tours cancer centers throughout the U.S.</p></div>
AACR To Host Congressional Briefing on National Cancer Moonshot Initiative119906/27/2016 2:14:45 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx72False2016-06-22T17:30:00ZAACR leaders invite National Cancer Institute’s acting director to discuss the research priorities of the National Cancer Moonshot Initiative;<br>five early-career cancer researchers will share their perspectives<div class="ExternalClass2A764C007A5841EC9EC59D6D4E6EB0F3"><p>To attend in-person, please RSVP to Rachel Salis-Silverman, <a href="mailto&#58;rachel.silverman@aacr.org" target="_blank">rachel.silverman@aacr.org</a> or 215-446-7159.&#160;</p><p>The congressional briefing will also be streamed LIVE on Facebook at 12&#58;05 p.m. EDT&#58; <a href="http&#58;//www.facebook.com/aacr.org" target="_blank">www.facebook.com/aacr.org</a>. </p><p>WASHINGTON, D.C. — The American Association for Cancer Research (AACR) will host a congressional briefing to discuss Vice President Biden's National Cancer Moonshot Initiative. The briefing, which is titled &quot;Seizing Today's Opportunities to Accelerate Cancer Research,&quot; will take place on Tuesday, June 28, from 12 p.m. to 1&#58;30 p.m. in Room 562 of the Dirksen Senate Office Building.</p><p><strong>WHAT&#58;&#160; </strong>The program will feature NCI Acting Director Douglas Lowy, MD, who will discuss the research priorities of the National Cancer Moonshot Initiative and provide an update on the status of the NCI's Blue Ribbon Panel, a group of external experts established to provide advice and ensure that the National Cancer Moonshot Initiative's goals and approaches are grounded in the best science.&#160; AACR President Nancy Davidson, MD, will convey the cancer community's excitement for progress already underway and articulate how the Cancer Moonshot has the potential to contribute to the advancement of the field. Following Dr. Lowy, the AACR will convene five early-career investigators for a panel discussion moderated by Dr. Davidson to elicit their fresh perspectives on areas of needed focus to achieve the Cancer Moonshot's goal of accomplishing a decade's worth of progress in five years.</p><p><strong>WHO&#58;</strong></p><ul><li><strong>Nancy Davidson, MD,</strong> President, AACR; Director, University of Pittsburgh Cancer Institute</li><li><strong>Margaret Foti, PhD, MD (hc),</strong> Chief Executive Officer, AACR</li><li><strong>Douglas Lowy, MD,</strong> Acting Director, National Cancer Institute (NCI)</li><li>Early-career Investigators</li><ul><li><strong>Kara A. Bernstein, PhD,</strong> University of Pittsburgh Medical School</li><li><strong>Major K. Lee IV, MD, PhD,</strong> Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center</li><li><strong>Christine M. Lovly, MD, PhD,</strong> Vanderbilt University School of Medicine</li><li><strong>Paul A. Northcott, PhD,</strong> St. Jude Faculty, St. Jude Children's Research Hospital</li><li><strong>Jose G. Trevino, II, MD,</strong> University of Florida College of Medicine</li></ul></ul><p><strong></strong>&#160;</p><p><strong>WHEN&#58;&#160;</strong> Tuesday, June 28, 2016;&#160;12 p.m. to 1&#58;30 p.m.</p><p><strong>WHERE&#58;</strong>&#160; Dirksen Senate Office Building, Room 562,&#160;Capitol Hill</p><p>The congressional briefing will also be streamed LIVE on Facebook at 12&#58;05 p.m. ET&#58; <a href="http&#58;//www.facebook.com/aacr.org" target="_blank"><span style="text-decoration&#58;underline;">www.facebook.com/aacr.org</span></a>.</p><p><strong>DETAILS&#58;&#160; </strong>The National Cancer Moonshot Initiative has galvanized the cancer community and has sparked a renewed and unprecedented national and international dialogue about ways to accelerate progress against cancer at this critical time of extraordinary scientific opportunities. The AACR is a trusted advisor to the Vice President, his staff, and the NCI Blue Ribbon Panel, in which 20 of the 28 panelists are also AACR members.</p><p>The goal for convening members of Congress and their staff with the NCI's acting director, early-career investigators, and AACR leadership is to educate policymakers and generate excitement on Capitol Hill for the National Cancer Moonshot Initiative by showcasing the increased potential for curing the more than 200 types of diseases we call cancer.</p><p>The AACR appreciates Senator Bob Casey's (D-Pennsylvania) support for this congressional briefing.</p><p><strong>Media Contact&#58;</strong><br>American Association for Cancer Research<br> Rachel Salis-Silverman<br> 215-446-7159 (office)<br> 267-970-3685 (cell)<br><a href="mailto&#58;rachel.silverman@aacr.org">rachel.silverman@aacr.org</a></p></div>